INTRODUCTION: For follicular lymphoma (FL) patients (Pts) in need of therapy, frontline
treatment with bendamustine-rituximab (BR) has become a standard treatment option. The …

Background: Bendamustine and rituximab (BR) has been a preferred regimen for frontline
therapy of patients (pts) with advanced stage follicular lymphoma (FL) since randomized …

Background: R-maintenance for 2 years is part of a standard treatment approach for
previously untreated follicular lymphoma. In this study we compared the efficacy and safety …

Abstract Background: The StiL Study NHL 7-2008 investigates the role of maintenance
duration with rituximab after induction with bendamustine-rituximab (BR) for first-line …

Background: Bendamustine and rituximab (BR) is a commonly chosen frontline treatment for
grade 1-2 (G 1-2) follicular lymphoma (FL). This regimen resulted in significantly longer …

Introduction: Maintenance rituximab (R) has been shown to improve progression-free
survival (PFS) in patients with follicular lymphoma (FL) after first-line R with …

Purpose: We sought to improve upon frontline bendamustine/rituximab (BR) induction
therapy followed by rituximab maintenance in untreated high-risk follicular lymphoma (FL) …

Bendamustine (B) with rituximab (R) is a standard frontline treatment for medically fit
follicular lymphoma (FL) patients. The safety and efficacy of maintenance rituximab (MR) …

Simple Summary The initial treatment for patients with advanced-stage follicular lymphoma
is usually a combo of immunochemotherapy called R-CHOP (rituximab, cyclophosphamide …

Background: The BIONIC study tested whether bortezomib (V) improved the complete
remission (CR) rate when added to standard bendamustine/rituximab (BR) induction in …